Alteogen strikes $285M deal with GSK subsidiary for innovative cancer drug delivery
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
The partnership initially will focus on cardiovascular and kidney diseases
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
This marks the second indication for which gumokimab has gained NDA review acceptance
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Subscribe To Our Newsletter & Stay Updated